vs
Side-by-side financial comparison of Prelude Therapeutics Inc (PRLD) and Sunshine Biopharma Inc. (SBFM). Click either name above to swap in a different company.
Sunshine Biopharma Inc. is the larger business by last-quarter revenue ($8.6M vs $6.5M, roughly 1.3× Prelude Therapeutics Inc). Sunshine Biopharma Inc. runs the higher net margin — -25.0% vs -303.5%, a 278.5% gap on every dollar of revenue. On growth, Prelude Therapeutics Inc posted the faster year-over-year revenue change (116.7% vs -10.6%).
Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.
PRLD vs SBFM — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.5M | $8.6M |
| Net Profit | $-19.7M | $-2.1M |
| Gross Margin | — | 35.3% |
| Operating Margin | -314.1% | -20.9% |
| Net Margin | -303.5% | -25.0% |
| Revenue YoY | 116.7% | -10.6% |
| Net Profit YoY | 38.9% | 0.8% |
| EPS (diluted) | $-0.26 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $8.6M | ||
| Q3 25 | $6.5M | $9.4M | ||
| Q2 25 | — | $9.4M | ||
| Q1 25 | — | $8.9M | ||
| Q4 24 | — | $9.6M | ||
| Q3 24 | $3.0M | $8.4M | ||
| Q2 24 | — | $9.3M | ||
| Q1 24 | — | $7.5M |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | $-19.7M | $-883.8K | ||
| Q2 25 | — | $-1.8M | ||
| Q1 25 | — | $-1.2M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | $-32.3M | $-1.2M | ||
| Q2 24 | — | $-494.3K | ||
| Q1 24 | — | $-1.3M |
| Q4 25 | — | 35.3% | ||
| Q3 25 | — | 32.6% | ||
| Q2 25 | — | 36.4% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 32.2% | ||
| Q3 24 | — | 34.0% | ||
| Q2 24 | — | 25.3% | ||
| Q1 24 | — | 31.2% |
| Q4 25 | — | -20.9% | ||
| Q3 25 | -314.1% | -11.5% | ||
| Q2 25 | — | -21.8% | ||
| Q1 25 | — | -14.6% | ||
| Q4 24 | — | -21.7% | ||
| Q3 24 | -1145.9% | -13.1% | ||
| Q2 24 | — | -13.6% | ||
| Q1 24 | — | -17.9% |
| Q4 25 | — | -25.0% | ||
| Q3 25 | -303.5% | -9.4% | ||
| Q2 25 | — | -18.8% | ||
| Q1 25 | — | -13.3% | ||
| Q4 24 | — | -22.5% | ||
| Q3 24 | -1075.7% | -14.2% | ||
| Q2 24 | — | -5.3% | ||
| Q1 24 | — | -17.0% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.26 | $-0.54 | ||
| Q2 25 | — | $-0.82 | ||
| Q1 25 | — | $-0.44 | ||
| Q4 24 | — | $49.77 | ||
| Q3 24 | $-0.43 | $-11.61 | ||
| Q2 24 | — | $-43.48 | ||
| Q1 24 | — | $-2.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $55.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $58.5M | $23.0M |
| Total Assets | $94.8M | $30.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $153.6M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $23.0M | ||
| Q3 25 | $58.5M | $24.2M | ||
| Q2 25 | — | $25.7M | ||
| Q1 25 | — | $22.7M | ||
| Q4 24 | — | $23.5M | ||
| Q3 24 | $156.4M | $25.0M | ||
| Q2 24 | — | $23.5M | ||
| Q1 24 | — | $24.8M |
| Q4 25 | — | $30.1M | ||
| Q3 25 | $94.8M | $31.5M | ||
| Q2 25 | — | $32.0M | ||
| Q1 25 | — | $29.2M | ||
| Q4 24 | — | $30.6M | ||
| Q3 24 | $197.2M | $30.1M | ||
| Q2 24 | — | $29.3M | ||
| Q1 24 | — | $31.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.1M | $-1.6M |
| Free Cash FlowOCF − Capex | — | $-1.6M |
| FCF MarginFCF / Revenue | — | -18.9% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.6M | ||
| Q3 25 | $-19.1M | $-727.8K | ||
| Q2 25 | — | $-1.3M | ||
| Q1 25 | — | $-1.7M | ||
| Q4 24 | — | $-3.4M | ||
| Q3 24 | $-27.3M | $-1.4M | ||
| Q2 24 | — | $-4.6M | ||
| Q1 24 | — | $-3.2M |
| Q4 25 | — | $-1.6M | ||
| Q3 25 | — | $-735.8K | ||
| Q2 25 | — | $-1.4M | ||
| Q1 25 | — | $-1.7M | ||
| Q4 24 | — | $-3.5M | ||
| Q3 24 | $-27.4M | $-1.9M | ||
| Q2 24 | — | $-5.6M | ||
| Q1 24 | — | $-3.2M |
| Q4 25 | — | -18.9% | ||
| Q3 25 | — | -7.8% | ||
| Q2 25 | — | -15.2% | ||
| Q1 25 | — | -19.3% | ||
| Q4 24 | — | -36.6% | ||
| Q3 24 | -912.0% | -22.2% | ||
| Q2 24 | — | -59.7% | ||
| Q1 24 | — | -43.1% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | 2.1% | 6.1% | ||
| Q2 24 | — | 10.5% | ||
| Q1 24 | — | 0.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
